Cargando…

Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study

BACKGROUND: Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [(18)F]-flortaucipir binding and of cortical atrophy, and their relationships with cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagarde, Julien, Olivieri, Pauline, Tonietto, Matteo, Rodrigo, Sébastian, Gervais, Philippe, Caillé, Fabien, Moussion, Martin, Bottlaender, Michel, Sarazin, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155356/ https://www.ncbi.nlm.nih.gov/pubmed/37138309 http://dx.doi.org/10.1186/s13195-023-01237-2

Ejemplares similares

Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type
por: Lagarde, Julien, et al.
Publicado: (2021)

Early alteration of the locus coeruleus in phenotypic variants of Alzheimer’s disease
por: Olivieri, Pauline, et al.
Publicado: (2019)

Impact of Donepezil on Brain Glucose Metabolism Assessed Using [(18)F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer’s Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide
por: Hugon, Gaëlle, et al.
Publicado: (2022)

Characterization of the initial complaint and care pathways prior to diagnosis in very young sporadic Alzheimer’s disease
por: Olivieri, Pauline, et al.
Publicado: (2021)

3T sodium MR imaging in Alzheimer’s disease shows stage-dependent sodium increase influenced by age and local brain volume
por: Haeger, Alexa, et al.
Publicado: (2022)

Acute Morphine Exposure Increases the Brain Distribution of [(18)F]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates
por: Auvity, Sylvain, et al.
Publicado: (2016)

Could Experimental Inflammation Provide Better Understanding of Migraines?
por: Reducha, Philip Victor, et al.
Publicado: (2022)

Longitudinal tau PET in ageing and Alzheimer’s disease
por: Jack, Clifford R, et al.
Publicado: (2018)

Modifications of the endosomal compartment in fibroblasts from sporadic Alzheimer’s disease patients are associated with cognitive impairment
por: Xicota, Laura, et al.
Publicado: (2023)

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
por: Chen, Shi-Dong, et al.
Publicado: (2021)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Supervised clustering for TSPO PET imaging
por: Schubert, Julia, et al.
Publicado: (2021)

Novel PET/SPECT Probes for Imaging of Tau in Alzheimer's Disease
por: Watanabe, Hiroyuki, et al.
Publicado: (2015)

Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
por: Sintini, Irene, et al.
Publicado: (2019)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

Exploring glia to better understand Alzheimer’s disease
por: Kim, Yoo Sung, et al.
Publicado: (2018)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

We could be better if we ate better
por: Velloso, Licio A.
Publicado: (2020)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease
por: Ossenkoppele, Rik, et al.
Publicado: (2020)

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
por: Yap, Steven Y, et al.
Publicado: (2021)

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
por: Guo, Yu, et al.
Publicado: (2021)

Deep learning improves utility of tau PET in the study of Alzheimer's disease
por: Zou, James, et al.
Publicado: (2021)

Plasma DYRK1A as a novel risk factor for Alzheimer's disease
por: Janel, N, et al.
Publicado: (2014)

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
por: Delabar, Jean M., et al.
Publicado: (2023)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients
por: Corlier, F, et al.
Publicado: (2015)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

Deep learning detection of informative features in tau PET for Alzheimer’s disease classification
por: Jo, Taeho, et al.
Publicado: (2020)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
por: Mohammadi, Zohreh, et al.
Publicado: (2023)

Stacked binding of a PET ligand to Alzheimer’s tau paired helical filaments
por: Merz, Gregory E., et al.
Publicado: (2023)

The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
por: Macedo, Arthur C., et al.
Publicado: (2023)

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2023)

Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
por: Govindpani, Karan, et al.
Publicado: (2017)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Advancing Tau-PET quantification in Alzheimer’s disease with machine learning: introducing THETA, a novel tau summary measure
por: Gebre, Robel K., et al.
Publicado: (2023)

China and SARS: could do better
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_626dvb3h40c6a34d305mdi14ni